Citations

Clear

1526 citation(s) found for "Sun, Bo".

Senescence‐Driven IL ‐ 17A Inflammatory Circuit Promotes Epithelial–Mesenchymal Transition ( EMT) and P
Ni, Yan, Ma, Yu , Ren, Zewen , Zhu, Yi, Duan, Runping , Qin, Lu, Chen, Yang, Ju, Rong , Qin, Yingyan , Wu, Mingxing , Ni, Yan , Ma, Yu, Liu, Liangping

Mayo Clinic

Aging Cell | March 25, 2026 | Volume: 25 | Issue: 4 | Pages: No page available

10.1111/acel.70456 | PMID 41876404 Get It

ABSTRACT Cataract is a leading cause of visual impairment worldwide, and its prevalence is increasing with population aging. The majority are age‐related cataracts (ARC), clinically classified into nuclear, cortical, and posterior subcapsular cataracts (PSC) by opacity location. Mechanisms of cataractogenesis remain incompletely understood. While cortical and nuclear cataracts are largely attributed to crystallin aggregation, such protein‐centric mechanisms fail to explain the early onset and axial location of PSC. Morphologically, PSC resembles posterior capsule opacification (PCO), a secondary cataract driven by epithelial–mesenchymal transition (EMT) of lens epithelial cells (LECs), suggesting LEC‐EMT may also contribute to PSC. Using clinically stratified human lens samples, we confirmed EMT marker expression across PSC subtypes. Transcriptomic profiling revealed that LECs, the lens's sole metabolically active cells, in age‐related PSC (ARC‐PSC), compared with age‐related nuclear cataract (ANC) and clear lenses, exhibit elevated EMT signatures tightly linked to senescence‐associated inflammatory signaling. Aqueous humor (AqH) profiling demonstrated a pro‐inflammatory milieu across PSC subtypes, with IL‐17A uniquely elevated in ARC‐PSC, consistent with transcriptomic findings. Integrated analyses support a model in which senescence functions as an upstream driver, whereby senescent LECs release SASP factors, including IL‐17A, that activate NF‐κB signaling to amplify inflammation, reinforce senescence, and drive EMT. In vitro, senolysis and IL‐17A blockade disrupted this loop, attenuating senescence‐ and EMT‐associated phenotypes. Collectively, our study demonstrates that senescent LECs sustain an IL‐17A–NF‐κB circuit that drives EMT and accelerates ARC‐PSC progression, positioning ARC‐PSC as a unique human context to study senescence‐induced epithelial remodeling in aging tissues.
Brain-Only Versus GI-Only Synucleinopathy: A Comprehensive Autopsy Study With Both IHC and SAA
Orru, Christina D., Beach, Thomas G., Adler, Charles H., Shill, Holly A., Driver-Dunckley, Erika, Mehta, Shyamal H. , Atri, Alireza, Lorenzini, Ileana , Qiji, Sanaria H., Intorcia, Anthony J., Hughson, Andrew G., Groveman, Bradley R. , King, Samantha, Parveen, Sabiha , Caughey, Byron, Serrano, Geidy E , Orru, Christina Doriana , Beach, Thomas G. , Adler, Charles H. , Shill, Holly A. , Driver‐Dunckley, Erika , Atri, Alireza , Hughson, Andrew G. , Alam, Parvez , Vascellari, Sarah , Caughey, Byron W. , Serrano, Geidy E.

Mayo Clinic

No container title available | March 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.18.26348355 | PMID 41929295 Get It

ABSTRACT Braak and others have proposed that Lewy body pathology (LBP) in Parkinson’s disease (PD) may arise not only in the brain but alternatively from an initial site in the gastrointestinal (GI) tract with subsequent passage to the central nervous system CNS through the vagus nerve or other routes. We tested this hypothesis by using both immunohistochemistry (IHC) and RT QuIC a form of alpha synuclein seed amplification assay (SAA) to detect alpha synuclein LBP in samples from selected brain regions and 10 GI tract sites taken from autopsies of 50 PD subjects and 128 elderly subjects without parkinsonism or dementia including 34 with IHC identified CNS incidental Lewy body disease (ILBD) and 94 with no Lewy body IHC pathology detected (NLB). A positive SAA or IHC result was restricted to the GI tract in only 2 subjects while LBP by either SAA or IHC was restricted to the brain in 11 subjects. To fairly compare GI-only with brain-only synucleinopathy, however, we would have to do SAA on brain samples from all ILBD and NLB cases in at least 4 critical brain regions: olfactory bulb, medulla, pons, and amygdala. Further SAA of brain regions is estimated, based on the proportional results to date, to potentially identify 21 additional brain-only LBP subjects, for a total of 32, if it were done on all of the NLB subjects. From this brain-only LBP is estimated to be 16 times more common than GI-only LBP. To assess the clinical impact of SAA-positive GI sites we found that the number of positive sites per subject is significantly correlated with UPDRS motor score and SCOPA-AUT GI related scores including those for salivation, straining, constipation, and bowel movement.
Long-Term Survival in High-Grade Serous Ovarian Cancer Compared With the General US Population: A 30-Year Landmark Analysis
Vitis, Luigi Antonio De , Larson, Melissa C., Atkinson, Hunter J., Block, Matthew S. , CLIBY, W, Couch, Fergus J., Dowdy, Sean C., Glaser, Gretchen E., Goergen, Krista M., Goode, E., Gostout, Bobbie S., Hartmann, Lynn C., Heinzen, Ethan P. , Huang, Yajue, Jatoi, Aminah , Jones, Monica B., Karow, Katie J., Keeney, Gary L., Kumar, Amanika, Langstraat, Carrie L., Lee, Sun-Hee , Mariani, A., Ostby, Stuart A. , Peethambaram, Prema P. , Podratz, Karl C. , Shahi, Maryam , Sherman, M., Sommerfield, Marla Kay, Wall, Vonda M., Weroha, S. John, Hendrickson, Andrea E. Wahner , Maurer, Matthew J., Bakkum-Gamez, Jamie, Oberg, Ann L. , Cliby, William A. , Couch, Fergus J. , Larson, Melissa C. , Glaser, Gretchen , Couch, Fergus J. , De Vitis, Luigi A, Jones, Monica, Glaser, Gretchen , Larson, Melissa C , Cliby, William A , Atkinson, Hunter J., Dowdy, Sean C. , Hartmann, Lynn C. , Kumar, Amanika , Langstraat, Carrie , Sherman, Mark E. , Sommerfield, Marla-Kay, Swisher, Elizabeth M. , Wall, Vonda M., Maurer, Matthew J. , Kaufmann, Scott H. , Bakkum‐Gamez, Jamie N.

Mayo Clinic

JCO Oncology Advances | March 20, 2026 | Volume: 3 | Issue: 1 | Pages: No page available

10.1200/oa-25-00142 | PMID 41918500 Get It

PURPOSE To compare mortality risk among long-term survivors of high-grade serous ovarian cancer (HGSOC) with that of the general US population and to examine how mortality and recurrence trends have evolved under changing treatment approaches. MATERIALS AND METHODS This is a retrospective cohort study including patients with histologically confirmed HGSOC treated at a single referral cancer center from 1991 to 2022. Mortality risk, expressed as standardized mortality ratios (SMRs, ratio of observed deaths in the study population to expected deaths in an age-matched US population), was assessed at diagnosis and yearly on patients without events (disease persistence, recurrence, or death from any cause). RESULTS A total of 2,074 consecutive patients were included. The median follow-up was 12.5 years (IQR, 11.7-13.8). Most patients were stage III (1,396, 69.2%), 1,299 (62.8%) underwent primary cytoreductive surgery, and 1,688 (87.4%) received platinum-taxane as first-line therapy. At diagnosis, the mortality rate was 7.40 times higher than that in the general population (95% CI, 7.04 to 7.77). By 7 event-free years, the 95% CI for the SMR included 1 for the first time, and at 10 years, the SMR was 1.05 (95% CI, 0.72 to 1.49), indicating no statistically significant excess mortality compared with the general population. In those event-free at 10 years, the 5-year cumulative incidence of ovarian cancer–related deaths (8.2% [95% CI, 4.2 to 16.0]) was comparable with that of non–ovarian cancer–related deaths (6.3% [95% CI, 2.9 to 13.8]). CONCLUSION In this cohort, mortality risk steadily declined for patients who remained event-free, approaching that of the general population by 7 years after diagnosis. These results emphasize the importance of individualized, long-term follow-up to address both recurrence risk and survivorship needs.
Angle-Free Ultrasound-assisted Technique for Difficult Lumbar Puncture to Enhance Precision and Success in Complex Spinal Anatomy: A Case Series with Longitudinal Learning Curve Analysis
Wang, Xuan, Luo, Yijun , Huang, Chanyan, Lu, Xiaolin , Diedrich, Daniel A. , Xiao, Ying , Wang, Xuan, Zhang, Xiaolong, Huang, Chanyan , Xiao, Ying

Mayo Clinic

No container title available | March 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-8901033/v1 Get It

Abstract Background Lumbar puncture is a routinely performed procedure, yet it presents significant challenges in patients with abnormal spinal anatomy, such as severe scoliosis or obesity. Conventional ultrasound-assisted neuraxial techniques, while superior to landmark-based methods, are constrained by two fundamental limitations: inaccurate projection of the probe’s geometric center onto the skin when the probe is tilted or rocked, and the difficulty of consistently replicating the exact probe angle during needle insertion. These limitations contribute to multiple needle passes, prolonged procedure time, and increased patient discomfort and complication risk. To address these issues, we developed a novel angle-free ultrasound-assisted technique designed to eliminate the need for replicating probe angulation during needle insertion. Case presentation: This angle-free approach was utilized for serial lumbar punctures in two patients with spinal muscular atrophy requiring repeated intrathecal nusinersen administration. Both patients presented with extreme anatomical complexity, including high body mass index (30 and 35.1 kg/m²) and severe scoliosis (Cobb angles 90° and 83°). The technique follows a three-step protocol: (1) Preprocedural imaging to select the optimal interlaminar space; (2) Ultrasound-guided postural adjustment until the probe could be held perpendicular to the bed edge and parallel to the floor while maintaining target visualization; (3) Needle insertion along this orthogonal trajectory. All 22 procedures (11 per patient) were completed successfully without persistent neurological complications. Procedural outcomes demonstrated a first-attempt success rate of 81.8% (Case 1) and 100% (Case 2), with first-pass success rates of 45.5% and 54.5%, respectively. Longitudinal analysis across sequential procedures revealed a consistent reduction in both the number of needle passes and needling time, reflecting a favorable learning curve. Conclusions The angle-free ultrasound-assisted neuraxial technique offers a valuable alternative for patients with complex spinal anatomy. By using real-time postural adjustments to achieve a needle trajectory, it enhances procedural precision and eliminates the technical hurdle of replicating probe angulation. The structured "4P" framework (Planning, Positioning, Perpendicular, Parallel) offers a practical guide for clinical adoption. The observed learning curve suggests that clinicians can readily acquire and apply this technique to manage such challenging cases.
Translating Histopathology Foundation Model Embeddings into Cellular and Molecular Features for Clinical Studies
Cui, Saishi , Sui, Zhining , Li, Ziyi, Grady, William M., Sun, Wei , Grady, William M. , Sun, Wei , Grady, William M , Matkowskyj, Kristina A. , Yu, Ming

Mayo Clinic

No container title available | March 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.17.711896 Get It

Abstract AI-powered pathology foundation models provide general-purpose representations of histopathological images by encoding image tiles into numerical embeddings. However, these embeddings are not directly interpretable in biological or clinical terms and must be translated into biologically meaningful features, such as cell-type composition or gene expression, to enable downstream clinical applications. To bridge this gap, we developed STpath, a framework that integrates histopathology image embeddings derived from existing pathology foundation models with matched, spatially resolved transcriptomics data. STpath consists of cancer-specific XGBoost models trained to infer cell-type compositions and gene expression from histopathology image tiles. We evaluated STpath in colorectal and breast cancer datasets and showed that it provides accurate estimates of the composition of major cell types and the expression of a subset of genes, with further performance gains achieved by combining embeddings from multiple foundation models. Finally, we demonstrated that STpath inferred features that can be used in downstream studies to evaluate their associations with clinical outcomes.
Modeling cis -regulatory variation in human brain enhancers across a large Parkinson’s Disease cohort
Sigalova, Olga , Pančíková, Alexandra , Man, Julie De , Theunis, Koen , Hulselmans, Gert , Konstantakos, Vasileios , Stuyven, Bram , Brabandere, Anton De, Geurts, Jarne , Mikorska, Antonina , Mukherjee, Shinjini , Vandereyken, Katy, Davie, Kristofer , Mahieu, Lukas, Adler, Charles H., Beach, Thomas G., Serrano, Geidy E., Voet, Thierry , Aerts, Stein , Sigalova, Olga M , De Man, Julie , Hulselmans, Gert J , De Brabandere, Anton , Abouelasrar Salama, Sara , Vandereyken, Katy , Davie, Kristofer , Mahieu, Lukas , Adler, C H , Beach, Thomas G , Serrano, Geidy E , Voet, Thierry , Demeulemeester, Jonas , Aerts, Stein , Adler, Charles H. , Beach, Thomas G. , Serrano, Geidy E.

Mayo Clinic

No container title available | March 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.15.711881 | PMID 41889906 Get It

Abstract Genome-wide association studies (GWAS) have linked more than a hundred non-coding genomic loci to Parkinson’s disease (PD) risk. Deciphering their functional impact on gene regulation requires cell type-aware modeling approaches to assess the effects of sequence variation on enhancer function and target gene expression. To address this challenge, we generated a comprehensive matched dataset from 190 human donors (115 controls and 75 PD), comprising long-read whole-genome sequencing alongside single nucleus multiome atlases (snATAC-seq and snRNA-seq for 3.1 and 1.1 million nuclei respectively) of the anterior cingulate cortex and substantia nigra. By integrating chromatin accessibility quantitative trait loci (caQTL), DNA methylation QTL (meQTL), and allele-specific chromatin accessibility (ASCA), we identified 53,841 high-confidence cis -acting genetic variants that modulate cell type-specific enhancer accessibility in one or both brain regions. We further demonstrate that sequence-to-function models can accurately predict the impact of these variants directly from the genomic sequence. Novel explainability approaches allowed stratifying these variants according to their regulatory function, with the majority disrupting specific transcription factor binding sites in a cell type specific manner. Integrating these “enhancer variants” (EV) with eQTL mapping and gene locus modeling linked a subset of EVs to their target genes. Finally, we applied these models to prioritize regulatory variants at known PD GWAS loci, bypassing statistical limitations in rare disease-relevant populations like dopaminergic neurons. All together, we establish a unique resource and new sequence modeling strategies to interpret functional non-coding variation in the human brain.
Herpesvirus genome integration in whole‐genome sequences of dementia and control cohorts
Piotrowski, Stacey L. , Allnutt, Mary Alice , Johnson, Kory, Ferrucci, Luigi, Morris, Huw, Hardy, John, Ryten, Mina, Logroscino, Giancarlo, Troncoso, Juan C. , Beach, Thomas G., Serrano, Geidy E., Cruchaga, Carlos, Ross, Owen A., Chiò, Adriano, Ding, Jinhui, Scholz, Sonja W. , Jacobson, Steven, Hardy, John , May, Patrick , Scholz, Sonja W , Hardy, John , May, Patrick , Houlden, Henry , Johnson, Kory, Tanaka, Toshiko , Ferrucci, Luigi , Ryten, Mina , Logroscino, Giancarlo , Beach, Thomas G. , Serrano, Geidy E. , Cruchaga, Carlos , Dickson, Dennis W. , Ross, Owen A. , Chiò, Adriano , Houlden, Henry , Dalgard, Clifton L. , Ding, Jinhui , Gibbs, J. Raphael , Traynor, Bryan J. , Jacobson, Steven

Mayo Clinic

Alzheimer's & Dementia | March 19, 2026 | Volume: 22 | Issue: 3 | Pages: No page available

10.1002/alz.71047 | PMID 41853978 Get It

Abstract INTRODUCTION The infectious hypothesis suggests that microbes like herpesviruses may play a role in the pathogenesis of Alzheimer's disease (AD) and other related dementias through methods that may include viral genome integration. The occurrence of herpesvirus genome integration in dementia patients has not been thoroughly characterized. METHODS Over 7500 total whole‐genome sequences from control, frontotemporal dementia/amyotrophic lateral sclerosis spectrum, Lewy body dementia (LBD), multiple system atrophy (MSA), and AD cohorts were screened for the integration of pathogen genomes using the PathSeq computational tool. RESULTS Low PathSeq scores for human herpesvirus 6 (HHV‐6) were consistent with the suspected integration of viral genome segments. The LBD and MSA cohorts had a significantly higher prevalence of this partial HHV‐6 genome integration. DISCUSSION This higher prevalence in both synucleinopathies was not noted in other herpesviruses, suggesting that the integration of HHV‐6 may play a role in a subset of these patients. Highlights Over 7500 whole‐genome sequences from controls and dementia patients were analyzed. Sequences consistent with integrated herpesviruses were identified using PathSeq. Prevalence of partial HHV‐6 integration was higher in synucleinopathies. Herpesviruses genome integration may play a role in subsets of dementia patients.
Delactylation of viral proteins by SIRT1 suppresses influenza A virus replication
Chen, Dongdong , Zhao, Gejie , Zhou, Jia, He, Shutong, Lv, Changjie , Chen, Yuhai, Zhu, Shouhai , Gao, Ming, Guo, Guijie , Guo, Guijie , Gao, Ming , Chen, Dongdong , Lv, Changjie , Gao, Ming , Zhu, Shouhai , Zhou, Jia, Sun, Peng

Mayo Clinic

mBio | March 18, 2026 | Volume: 17 | Issue: 4 | Pages: No page available

10.1128/mbio.02489-25 | PMID 41848315 Get It

ABSTRACT Lactylation, a protein post-translational modification driven by lactate, plays crucial roles in various physiological and pathological processes. However, the function and underlying mechanisms of lactylation in infection and pathogenesis of influenza A virus (IAV) remain poorly understood. Here, we demonstrated that sirtuin 1 (SIRT1) suppressed IAV replication by mediating delactylation of viral proteins. We found that IAV infection significantly downregulated the expression of SIRT1. Functional studies revealed that depletion of SIRT1 markedly enhanced replication of IAV, whereas overexpression of SIRT1 attenuated the viral replication. Mechanistically, we observed that SIRT1 interacted with IAV NP, PA, PB1, and PB2 proteins, components of the viral ribonucleoprotein (vRNP) complex, and restrained the activity of the vRNP complex, thereby repressing transcription and replication of the IAV genome. Furthermore, we identified that viral NP, PA, PB1, and PB2 proteins underwent lactylation during IAV infection, and SIRT1 facilitated the delactylation of NP, PA, and PB2. Loss of SIRT1 enhanced the lactylation of NP, PA, and PB2, while overexpression of SIRT1 impaired lactylation of these viral proteins during IAV infection. Moreover, inhibition or depletion of lactate dehydrogenase A (LDHA) robustly reduced the lactylation of NP, PA, and PB2, thereby abolishing the promotion of IAV replication caused by SIRT1 deficiency, suggesting that SIRT1 repressed IAV replication via delactylation of viral NP, PA, and PB2 proteins. Together, these results uncover a mechanism that SIRT1 suppresses IAV replication via delactylation of the vRNP components and elicit a critical role for the lactylation of viral proteins in regulating IAV infection and pathogenesis. IMPORTANCE Lactylation plays vital roles in diverse pathological processes. However, the relationship between lactylation and influenza A virus (IAV) infection remains largely unexplored. Particularly, little information is available about the lactylation of viral proteins and their roles in the IAV pathogenesis. Here, viral proteins (NP, PA, PB1, and PB2) were identified to become lactylated during IAV infection. SIRT1 interacted with and promoted the delactylation of viral NP, PA, and PB2 proteins, thereby restraining the vRNP activity and inhibiting the viral transcription and replication. Interestingly, the expression of SIRT1 decreased following IAV infection, suggesting that IAV had evolved a mechanism to downregulate the SIRT1 expression, thereby ensuring appropriate lactylation of viral proteins and facilitating the IAV replication. Together, these findings reveal a critical role for the lactylation of viral proteins in regulating the replication of IAV and provide an important insight into the complicated interplay between the host and IAV.
Preliminary Safety and Efficacy of Navitoclax Plus Ruxolitinib in Janus Kinase Inhibitor‐Naïve Patients With Myelofibrosis From the Multicenter, Open‐Label, Phase 2 Study (REFINE)
Passamonti, Francesco, Foran, J., Tandra, Anand, Stefano, Valerio De, Mattour, Ahmad, McMullin, Mary Frances , Perkins, Andrew C. , Rodríguez‐Macías, Gabriela , Sibai, Hassan , Polepally, Akshanth R. , Sun, Yan, Chopra, Avijeet S., Harb, Jason G., Qin, Qin, Potluri, Jalaja , How, Jonathan, Foran, James M , McMullin, Mary Frances , Perkins, Andrew C , Passamonti, Francesco , Foran, James M. , Stefano, Valerio De , Fox, María Laura , Qin, Qin Q.

Mayo Clinic

Hematological Oncology | March 18, 2026 | Volume: 44 | Issue: 2 | Pages: No page available

10.1002/hon.70180 | PMID 41846295 Get It

ABSTRACT Myelofibrosis is characterized by perturbation of the JAK/STAT pathway and upregulation of anti‐apoptotic factors leading to myeloproliferation, bone marrow fibrosis (BMF), extramedullary hematopoiesis, splenomegaly, and cytopenias. Navitoclax, a potent oral B‐cell lymphoma (BCL)‐X L /BCL‐2 inhibitor, promotes apoptosis of malignant myelofibrosis cells. Herein, we present results of Cohort 3 of the Phase 2 REFINE study (NCT03222609), which evaluated efficacy and safety of navitoclax plus ruxolitinib in JAKi‐naïve patients with myelofibrosis. JAKi‐naïve patients with primary or secondary myelofibrosis (≥ 18 years with splenomegaly, DIPSS intermediate‐2 and high‐risk myelofibrosis, and ECOG 0–2) and platelet count > 100 × 10 9 /L were enrolled and treated with navitoclax 100 mg once daily (QD) or 200 mg QD according to platelet count (≤ 150 × 10 9 /L or > 150 × 10 9 /L, respectively). Ruxolitinib was given twice daily (dose per label). Primary endpoint: spleen volume reduction of ≥ 35% (SVR 35 ) at week 24. Secondary endpoints: ≥ 50% reduction in total symptom score (TSS 50 ) at week 24, change in grade of BMF, anemia response, and safety. Thirty‐two patients received ≥ 1 dose of navitoclax plus ruxolitinib. Median (range) duration of follow‐up was 44 months (5–58). 63% (20/32) of patients achieved SVR 35 at week 24; median (range) time to first SVR 35 was 12 weeks (11─48). Of 24 evaluable patients, 21% achieved ≥ 50% reduction in driver gene variant allele frequency (VAF). Of 27 evaluable patients, 11 (41%) achieved TSS 50 at week 24; median (range) time to first TSS 50 of 3 weeks (0─16). BMF improved from baseline by ≥ 1 grade in 13/27 patients (48%) at any time on study. Anemia response rates were 38% (5/13) for transfusion‐independent and 100% (2/2) for transfusion‐dependent patients. No bleeding events or deaths were attributed to navitoclax. These findings suggest navitoclax plus ruxolitinib has a tolerable safety profile and provides clinically meaningful improvements for JAKi‐naïve patients with myelofibrosis. Trial Registration NCT03222609.
Epigenetically controlled endothelial promyelocytic leukemia drives liver inflammation and fibrosis
Gan, Can, Lai, Enjiang, Tai, Yang, Chen, Shuai, Zhao, Chong, Dai, Wenting , Yang, Zhu, Li, Bei , Lan, Tian, Xiao, Yang, Guo, Yangkun, Chen, Jiaxin , Wei, Bo, Cao, Sheng , Liu, Mengfei, Tacke, Frank, Tang, Chengwei, Shah, Vijay H. , Yu, Haopeng, Wang, Fei, Huang, Zhiyin , Gao, Jinhang, Gao, Jinhang , Gao, Jinhang , Lai, Enjiang, Tai, Yang, Lan, Tian, Xiao, Yang, Guo, Yangkun, Wei, Bo , Che, Zhaodi , Tacke, Frank , Tang, Chengwei , Yu, Haopeng

Mayo Clinic

Journal of Clinical Investigation | March 17, 2026 | Volume: 136 | Issue: 11 | Pages: No page available

10.1172/jci196730 | PMID 41842990 Get It

Cellular and molecular heterogeneity in the liver has been increasingly recognized to drive liver fibrosis progression, but the particular events that occur initially in response to liver injury and trigger immune cell recruitment remain unclear. Here, we identify epigenetically aberrant liver sinusoidal endothelial cells (LSECs) as key players in this process. Mechanistically, the epigenetic readers like bromodomain-containing protein 4–dependent (BRD4-dependent) super enhancers (SEs) activate proinflammatory genes, including promyelocytic leukemia (PML). The PML protein, in turn, binds BRD4 and amplifies proinflammatory angiocrine signaling through phase separation–dependent SE activation via PML/BRD4 condensate formation. In mouse models, LSEC-specific depletion of the PML/BRD4 complex mitigates liver inflammation and fibrosis. Single-cell RNA-seq reveals that epigenetically aberrant LSECs exhibit a reprogrammed proinflammatory angiocrine landscape in mouse fibrotic livers. TIMP1 + LSECs promote the recruitment of CD63 + monocyte–derived macrophages (MoMFs) during liver fibrosis progression. Thereby, PML/BRD4 in LSECs governs inflammatory immune cell recruitment in liver fibrosis. Pharmacological BRD4 inhibition or epigenetic PML-SE repression alleviates liver inflammation and fibrosis. In conclusion, PML/BRD4-mediated SE activation via phase separation drives proinflammatory angiocrine signaling in LSECs, initiating the inflammatory cascade and subsequent immune cell recruitment during liver fibrosis.